Candriam Luxembourg S.C.A. Takes Position in AveXis Inc. (AVXS)
Candriam Luxembourg S.C.A. purchased a new position in shares of AveXis Inc. (NASDAQ:AVXS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 48,000 shares of the company’s stock, valued at approximately $1,825,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in AVXS. Pictet Asset Management Ltd. acquired a new stake in AveXis during the first quarter worth $536,000. BlackRock Inc. acquired a new stake in AveXis during the first quarter worth $563,000. JPMorgan Chase & Co. acquired a new stake in AveXis during the first quarter worth $976,000. BlackRock Institutional Trust Company N.A. acquired a new stake in AveXis during the first quarter worth $1,024,000. Finally, State Street Corp acquired a new stake in AveXis during the first quarter worth $1,058,000. Institutional investors and hedge funds own 54.46% of the company’s stock.
AveXis Inc. (NASDAQ:AVXS) traded up 1.92% during trading on Monday, hitting $42.00. The company’s stock had a trading volume of 207,961 shares. The company has a 50-day moving average of $39.32 and a 200 day moving average of $35.31. The firm’s market cap is $966.55 million. AveXis Inc. has a one year low of $17.40 and a one year high of $47.76.
AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.09. On average, equities analysts forecast that AveXis Inc. will post ($3.30) earnings per share for the current year.
AVXS has been the subject of a number of recent analyst reports. Zacks Investment Research raised AveXis from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Tuesday, August 16th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of AveXis in a research report on Friday, August 12th. Jefferies Group raised AveXis from a “hold” rating to a “buy” rating and set a $42.00 price target for the company in a research report on Friday, August 12th. Finally, Wells Fargo & Co. began coverage on AveXis in a research report on Friday, July 15th. They set a “market perform” rating for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $47.00.
In other news, insider Paul B. Manning sold 289,855 shares of the company’s stock in a transaction on Tuesday, September 13th. The stock was sold at an average price of $34.50, for a total transaction of $9,999,997.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
AveXis Company Profile
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis Inc. (NASDAQ:AVXS).
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.